EBV Infection Control Precautions
Standard precautions are sufficient for patients with active Epstein-Barr virus (EBV) infection in routine healthcare settings—no special isolation or transmission-based precautions are required.
Rationale and Evidence Base
EBV is primarily transmitted through saliva and close personal contact, not through airborne or droplet routes in typical healthcare encounters. The virus does not require the enhanced precautions used for highly transmissible respiratory or contact-spread pathogens. The available guidelines focus on standard infection control practices rather than EBV-specific isolation measures 1.
Recommended Precautions
Standard Precautions Apply
Hand hygiene is the cornerstone of infection control:
- Perform hand hygiene with soap and water when hands are visibly soiled or contaminated with blood or body fluids 1
- Use alcohol-based hand rub when hands are not visibly soiled 1
- Always perform hand hygiene:
Personal protective equipment (PPE):
- Wear gloves when potential contact with blood, saliva, or mucous membranes exists 1
- Use surgical mask and eye protection only during procedures likely to generate splashing or spattering of body fluids 1
- Protective gowns are needed only if soiling with body fluids is anticipated 1
Practical Infection Control Measures
For general patient care:
- No private room required unless patient has other indications
- No special respiratory precautions (no N95 masks or negative pressure rooms)
- Standard room cleaning and disinfection protocols are adequate
Minimize exposure to infectious secretions:
- Avoid sharing eating utensils or drinking containers 3
- Practice good respiratory hygiene if patient has pharyngitis
- Healthcare workers should avoid direct contact with patient saliva when possible 3
Special Populations Requiring Enhanced Monitoring
Immunocompromised Patients
While standard precautions remain appropriate for infection control, certain high-risk populations require clinical monitoring (not isolation):
Post-transplant patients (allogeneic hematopoietic stem cell transplant):
- Prospective EBV DNA monitoring by quantitative PCR is recommended starting no later than 4 weeks post-transplant 4
- Weekly testing in high-risk patients for at least 4 months 4
- This is for disease surveillance, not infection control
Solid organ transplant recipients:
- Regular EBV viral load monitoring by PCR 3
- Focus on early detection of post-transplant lymphoproliferative disorder (PTLD), not preventing transmission
Common Pitfalls to Avoid
- Do not place EBV-infected patients in isolation unless they have concurrent infections requiring transmission-based precautions
- Do not use droplet or airborne precautions for EBV—these are unnecessary and waste resources
- Do not restrict visitors based solely on EBV infection status
- Do not confuse clinical monitoring (in transplant patients) with infection control precautions—these serve different purposes
Key Distinction
The extensive monitoring protocols described in transplant guidelines 4 are for detecting EBV reactivation and preventing PTLD, not for preventing person-to-person transmission. Standard precautions adequately prevent nosocomial EBV transmission in healthcare settings.